Medivir
Medivir AB is a Swedish pharmaceutical company focused on the development of innovative treatments for serious diseases. The company specializes in the research and development of small molecule drugs, with a particular emphasis on oncology and rare diseases. Medivir's portfolio includes both proprietary projects and outlicensed assets, allowing them to leverage partnerships for broader market reach. With a strong financial position and strategic collaborations, Medivir aims to advance its clinical projects and create long-term value for shareholders and patients alike.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueIncludes drugs for cancer treatment such as remetinostat and birinapant.
Focuses on treatments for rare conditions like Osteogenesis Imperfecta.
Includes products like Xerclear for skin conditions.
Involves drugs for animal health, such as VBX-1000.
Customers
Medivir's customer base primarily consists of pharmaceutical companies and healthcare providers seeking innovative treatments for cancer and rare diseases. The company also targets veterinary markets through partnerships for animal health products. Medivir's licensing agreements enable them to reach global markets, leveraging partners' distribution networks. Additionally, the company's focus on orphan drug designations attracts interest from stakeholders looking for exclusive market opportunities.
License Medivir's oncology and rare disease treatments for distribution.
Utilize Medivir's drugs for treating patients with rare diseases.
Adopt VBX-1000 for treating canine periodontitis.
Strategy
Medivir's strategic priorities include advancing its clinical pipeline, particularly in oncology and rare diseases. The company aims to leverage orphan drug designations to secure market exclusivity and regulatory support. Medivir is focused on strengthening its financial position through strategic partnerships and licensing agreements. The company also seeks to maximize the value of its projects by demonstrating clinical proof-of-concept and expanding its market reach.
To bring innovative treatments to market
To secure market exclusivity and regulatory support
To support ongoing and future clinical developments
Geography
Medivir operates primarily out of Sweden, with a focus on expanding its market presence through global partnerships. The company's licensing agreements with international partners allow it to reach markets in North America and Europe. Medivir's strategic collaborations provide access to regulatory support and market exclusivity, particularly in the U.S. The company's operations are influenced by currency exposure due to contracts in multiple currencies.
Risks
Medivir faces significant risks inherent in pharmaceutical development, including high costs and regulatory challenges. The company's reliance on partnerships and licensing agreements exposes it to potential market fluctuations and partner performance risks. Currency exposure due to multi-currency contracts adds financial risk. Additionally, the competitive landscape in oncology and rare diseases poses challenges to market entry and product differentiation.
- Regulatory challengesImpact: CriticalLikelihood: Medium
Complex approval processes for new drugs
- Partnership performanceImpact: HighLikelihood: Medium
Dependence on partners for market access
- Currency exposureImpact: HighLikelihood: Low
Multi-currency contracts affecting financial stability
Accounting
Judgemental itemsAffects timing and reporting of financial results
Impact: high
Influences financial stability and reporting
Impact: medium
Similar listed companies
Publicly listed companies with a comparable business focus.
Vimian Group
VIMIAN · Health Care
Vimian Group is a company focused on the animal health sector, providing a range of products and services across four segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics.
BioInvent International
BINV · Health Care
BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy.
Mereo BioPharma Group plc
MREO · Pharmaceutical Preparations
Mereo BioPharma Group plc is a biopharmaceutical company focused on developing late-stage therapies for rare diseases.
Medicus Pharma Ltd.
MDCXW · Pharmaceutical Preparations
Merck & Co., Inc.
MRK · Pharmaceutical Preparations
Moberg Pharma
MOB · Health Care
Moberg Pharma AB is a Swedish pharmaceutical company focused on the development and commercialization of medical products, particularly in the area of dermatology.
Last updated: 24/09/2026